US Stock Market Move | AgomAb Therapeutics (AGMB.US) debuts on the US stock market, opening with a drop of over 13%.
Opening down more than 13%, the IPO price is $16.
On Friday, AgomAb Therapeutics (AGMB.US) debuted on the US stock market, opening down more than 13% with an IPO price of $16. AgomAb Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative disease-modifying therapies for immune and inflammatory diseases. The company's initial focus is on chronic fibrotic conditions with high unmet medical needs, by targeting the key fibrosis signaling pathway - the transforming growth factor-beta (TGF) pathway. Its lead candidate drug, ontunisertib (AGMB-129), is a selective, potent, orally bioavailable ALK5 (TGFR1) small molecule inhibitor primarily aimed at fibrotic stricturing Crohn's disease (FSCD).
Related Articles
US Stock Market Move | Organic children's snack manufacturer Once Upon a Farm (OFRM.US) lands on the US stock market with an opening increase of over 15%.
US Stock Market Move | SpyGlass Pharma (SGP.US) debuted on the US stock market with a opening surge of over 43%.
NIO Inc. Sponsored ADR Class A (NIO.US) achieved 100 million battery swaps, with US stock opening soaring more than 10%.
US Stock Market Move | Organic children's snack manufacturer Once Upon a Farm (OFRM.US) lands on the US stock market with an opening increase of over 15%.
US Stock Market Move | SpyGlass Pharma (SGP.US) debuted on the US stock market with a opening surge of over 43%.
NIO Inc. Sponsored ADR Class A (NIO.US) achieved 100 million battery swaps, with US stock opening soaring more than 10%.
